|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CURRENT ASSETS: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Other accounts receivable and prepaid expenses | ||||||||||||||||||||
| Trade receivables | ||||||||||||||||||||
| Other receivables | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| NON-CURRENT ASSETS: | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Total long-term assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| CURRENT LIABILITIES: | ||||||||||||||||||||
| Accrued expenses and other payables | ||||||||||||||||||||
| Short Term Loans | ||||||||||||||||||||
| Related Parties | ||||||||||||||||||||
| Short-term credit | ||||||||||||||||||||
| Trade accounts payable | ||||||||||||||||||||
| Short-term operating lease liabilities | ||||||||||||||||||||
| Other accounts payable | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| NON-CURRENT LIABILITIES: | ||||||||||||||||||||
| Long-term loan from a related party | ||||||||||||||||||||
| Long-term loans from a related party | ||||||||||||||||||||
| Long-term operating lease liabilities | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total long-term liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| STOCKHOLDERS’ EQUITY (DEFICIENCY): | ||||||||||||||||||||
| Common stock of $0.01 par value – Authorized: 150,000,000, issued and outstanding 112,033,909 as of September 30, 2023 and as of December 31, 2022; | ||||||||||||||||||||
| Series D Convertible Preferred stock, $0.01 par value - Authorized: 110,000 shares; issued and outstanding: 0 shares as of December 31, 2022 and 110,000 shares as December 31, 2021 | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Series C Preferred Stock | ||||||||||||||||||||
| Series D Preferred Stock | ||||||||||||||||||||
| Capital reserve from transaction with a major stockholder | ||||||||||||||||||||
| Stock based compensation | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ deficiency | ||||||||||||||||||||
| Total liabilities and stockholders’ equity (deficiency) | ||||||||||||||||||||
Loading...
